SkinBioTherapeutics : Positive data for AxisBiotix-Ps™ food supplement consumer study unveiled

Add title here

• Bullet points here

• Bullet points here TM

BRIGHT consumer study of AxisBiotix-Ps

• BulletMaypoints2021 here

Presentation by:

Stuart Ashman, CEO

Professor Cath O'Neill, CSO

Disclaimer

The information contained in these slides and any accompanying verbal presentation,Addany question and answertitlesession and any documenthereor material distributed at or in connection with the verbal presentation (together, the "Presentation") have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). Reliance upon this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all amounts invested. If any person is in any doubt as to the contents of this Presentation, they should seek independent advice from a person who is authorised for the purposes of FSMA and who specialises in advising on investments of this kind. This Presentation is being supplied to you solely for your information and does not purport to contain all information that may be required to evaluate SkinBioTherapeutics plc (the "Company"). This Presentation has been prepared by, and is the sole responsibility of, the Company. The directors of the Company have taken all reasonable care to ensure that the facts stated herein are true to the best of their knowledge, information and belief.

This Presentation does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied upon in connection with, or act as any inducement to enter into any contract. Any investment in shares in the Company should only be made by you on the basis of your own judgment as to the merits of the suitability of the shares for your purposes, having taken all such professional advice you consider necessary or appropriate in the circumstances.

No reliance may be placed for any purpose whatsoever on the information or opinions•containedBulletin this Presentationpointsor on its completeness,hereaccuracy or fairness thereof, nor is any responsibility accepted for any errors, misstatements in, or omission from, this Presentation or any direct or consequential loss however arising from any use of, or reliance on, this Presentation or otherwise in connection with it.

This Presentation may not be reproduced or redistributed, in whole or in part, to any other person, or published, in whole or in part, for any purpose without the prior consent of the Company. The contents of this Presentation are confidential and are subject to updating, completion, revision, further verification and amendment without•noticeBullet.points here

The Presentation is being distributed on request only to, and is directed at, authorised persons or exempt persons within the meaning of FSMA or any order made thereunder or to those persons falling within the following articles of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Financial Promotion Order"); Investment Professionals (as defined in Article 19(5)) or are eligible counterparties within the meaning given in COBS 3.6.1 of the FSA Handbook as at 1 November 2007; High Net Worth Companies (as defined in Article 49(2)) and Members or Creditors of the Company (as defined in Article 43(2)) as well as persons to who distribution may otherwise lawfully be made (all such persons being "Relevant Persons"). Any person who is not a Relevant Person should not•relyBulleton this Presentation norpointstake any action upon it buthereshould return it immediately to the Company.

This Presentation is exempt from the general restriction in section 21 of FSMA relating to the communication of invitations or inducements to engage in investment activity on the grounds that it is made only to certain categories of persons.

Neither this Presentation nor any copy of it should be distributed, directly or indirectly, by any means (including electronic transmission) to any persons with addresses in the United States of America (or any of its territories or possessions) (together, the "US"), Australia, Canada, France, Japan, New Zealand, the Republic of Ireland,• Bulletthe Republic of South Africapointsor Switzerland, or to anyherecorporation, partnership or other entity created or organised under the laws thereof, or in any other country outside the United Kingdom where such distribution may lead to a breach of any legal or regulatory requirement. The recipients should inform themselves about and observe any such requirements or relationship.

The Company's ordinary shares have not been, and are not expected to be, registered under the United States Securities Act 1933, as amended, (the "US Securities Act") or under the securities laws of any other jurisdiction, and are not being offered or sold, directly or indirectly, within or into the US, Australia, Canada, France, Japan,• BulletNew Zealand, the Republicpointsof Ireland, the Republichereof South Africa or Switzerland, or to, or for the account or benefit of, any US persons or any national, citizen or resident of the US, Australia, Canada, France, Japan, New Zealand, the Republic of Ireland, the Republic of South Africa or Switzerland, unless such offer or sale would qualify for an exemption from registration under the US Securities Act and/or any other applicable securities laws.

This Presentation or documents referred to in it contain forward-looking statements. These statements relate to the future prospects developments and business strategies of the Company and its subsidiaries (the "Group"). Forward-looking statements are identified by the use of such terms as "believe", "could", "envisage", "estimate", "potential", "intend", "may", "plan", "will" or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in this Presentation are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Group's actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements. These forward-looking statements speak only as at the date of this Presentation. The Company is under no obligation to, and expressly disclaims any intention to, update or revise such forward-looking statements, estimates or projections.

By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you are a Relevant Person (as defined above); (ii) you will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part,

• for any purpose and (iii) you have read and agree to comply with the contents of this disclaimer.

AxisBiotix-PsTM introductionAdd title here

§ BRIGHT study summary	• Bullet points here
§ Product description
• Bullet points here
§ Psoriasis - condition and treatment
§ BRIGHT study set-up	• Bullet points here

§ Food supplement results	• Bullet points here

• Sample participant responses • Bullet points here
• Commercial strategy
• Company summary

3

Introduction

• Highly positive results from BRIGHT consumer study where majority of participants had sensitive skin conditions, such as psoriasis
• Over 72% of psoriasis participants who took the product for the full 56 days, reported overall improvements to their skin, across four factors:

§	Itchiness (76%)	§	Irritability (73%)
§	Redness (75%)	§	Flaky patches (65%)

• Participants who responded positively about skin health also recorded positive improvements to their general health and well being
• • Energy levels, sleep and mood

Next steps:

• Scale-upof manufacture for commercial launch during Q4 2021
• AxisBiotix-PsTM will be SkinBioTherapeutics' first commercial product; other products in the pipeline

4

AxisBiotix-Ps™ Add title

• Objective: to use bacteria to modulate the
  immune system and enhance the• Bulletgut barrierpoints
• Targeting relationship between gut and skin, and
  its role in skin conditions such as• Bulletpsoriasis points
• Proprietary blend of probiotics (live bacteria)
• • Bullet points
• Designed to be taken daily as a single sachet

dissolved in water	• Bullet points
§ Formulation and manufacturing partner,
Winclove Probiotics	• Bullet points

5